.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Chinese Patent Office
AstraZeneca
US Army
QuintilesIMS
Boehringer Ingelheim
Merck
Medtronic
McKinsey
Novartis

Generated: November 19, 2017

DrugPatentWatch Database Preview

Lamivudine; zidovudine - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for lamivudine; zidovudine and what is the scope of lamivudine; zidovudine freedom to operate?

Lamivudine; zidovudine
is the generic ingredient in two branded drugs marketed by Mylan Pharms Inc, Aurobindo Pharma Ltd, Pharmacare, Hetero Labs Ltd Iii, Strides Pharma, Lupin Ltd, Viiv Hlthcare, Hetero Labs Ltd V, and Teva Pharms, and is included in ten NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Lamivudine; zidovudine has forty-one patent family members in twenty-eight countries and one supplementary protection certificate in one country.

There are twenty-eight drug master file entries for lamivudine; zidovudine. Twenty-four suppliers are listed for this compound. There are sixteen tentative approvals for this compound.

Summary for lamivudine; zidovudine

Tentative approvals for LAMIVUDINE; ZIDOVUDINE

Applicant Application No. Strength Dosage Form
u► Subscribe150MG; 300MG; 200MGTABLET; ORAL
u► Subscribe150MG; 300MG; 600MGTABLET; ORAL
u► Subscribe150MG; 300MG; 300MGTABLET; ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hetero Labs Ltd Iii
LAMIVUDINE AND ZIDOVUDINE
lamivudine; zidovudine
TABLET;ORAL079124-001Sep 17, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Aurobindo Pharma Ltd
LAMIVUDINE AND ZIDOVUDINE
lamivudine; zidovudine
TABLET;ORAL202418-001May 15, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Lupin Ltd
LAMIVUDINE AND ZIDOVUDINE
lamivudine; zidovudine
TABLET;ORAL090246-001May 15, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms
LAMIVUDINE AND ZIDOVUDINE
lamivudine; zidovudine
TABLET;ORAL079081-001May 25, 2011ABRXNoNo► Subscribe► Subscribe► Subscribe
Hetero Labs Ltd V
LAMIVUDINE AND ZIDOVUDINE
lamivudine; zidovudine
TABLET;ORAL203259-001Feb 3, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
Viiv Hlthcare
COMBIVIR
lamivudine; zidovudine
TABLET;ORAL020857-001Sep 26, 1997ABRXYesYes► Subscribe► Subscribe ► Subscribe
Aurobindo Pharma Ltd
LAMIVUDINE AND ZIDOVUDINE
lamivudine; zidovudine
TABLET;ORAL077558-001May 5, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Pharmacare
LAMIVUDINE AND ZIDOVUDINE
lamivudine; zidovudine
TABLET;ORAL022018-001Mar 17, 2017BXRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
LAMIVUDINE AND ZIDOVUDINE
lamivudine; zidovudine
TABLET;ORAL204005-001Aug 28, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
Strides Pharma
LAMIVUDINE AND ZIDOVUDINE
lamivudine; zidovudine
TABLET;ORAL079128-001May 13, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: lamivudine; zidovudine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv Hlthcare
COMBIVIR
lamivudine; zidovudine
TABLET;ORAL020857-001Sep 26, 1997► Subscribe► Subscribe
Viiv Hlthcare
COMBIVIR
lamivudine; zidovudine
TABLET;ORAL020857-001Sep 26, 1997► Subscribe► Subscribe
Viiv Hlthcare
COMBIVIR
lamivudine; zidovudine
TABLET;ORAL020857-001Sep 26, 1997► Subscribe► Subscribe
Viiv Hlthcare
COMBIVIR
lamivudine; zidovudine
TABLET;ORAL020857-001Sep 26, 1997► Subscribe► Subscribe
Viiv Hlthcare
COMBIVIR
lamivudine; zidovudine
TABLET;ORAL020857-001Sep 26, 1997► Subscribe► Subscribe
Viiv Hlthcare
COMBIVIR
lamivudine; zidovudine
TABLET;ORAL020857-001Sep 26, 1997► Subscribe► Subscribe
Viiv Hlthcare
COMBIVIR
lamivudine; zidovudine
TABLET;ORAL020857-001Sep 26, 1997► Subscribe► Subscribe
Viiv Hlthcare
COMBIVIR
lamivudine; zidovudine
TABLET;ORAL020857-001Sep 26, 1997► Subscribe► Subscribe
Viiv Hlthcare
COMBIVIR
lamivudine; zidovudine
TABLET;ORAL020857-001Sep 26, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: lamivudine; zidovudine

Country Document Number Estimated Expiration
Spain2171158► Subscribe
Australia1736192► Subscribe
Singapore52455► Subscribe
Slovakia125793► Subscribe
Russian Federation2102393► Subscribe
European Patent Office0517145► Subscribe
Ireland20020782► Subscribe
Norway301713► Subscribe
African Regional IP Organization (ARIPO)9200395► Subscribe
Australia656379► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: LAMIVUDINE; ZIDOVUDINE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0022France► SubscribePRODUCT NAME: ABACAVIR SULFATE; LAMIVUDINE; REGISTRATION NO/DATE: EU/1/04/298/001 20041217
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Johnson and Johnson
QuintilesIMS
Colorcon
Harvard Business School
Cerilliant
Chubb
Chinese Patent Office
Dow
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot